How Liraglutide Is Stored: Stability and Handling, Per the Research

Liraglutide is a prescription glucagon-like peptide-1 (GLP-1) receptor agonist marketed in approved prefilled multi-dose pens. This page does not describe how any person should handle, prepare or administer it. The sections below separate three different kinds of information: what approved product labeling states, what compound-specific peer-reviewed literature on liraglutide and related GLP-1 analogues reported, and what is general peptide-stability science that has not been measured in liraglutide specifically. Each section says which category it belongs to. For background on the molecule itself, see the liraglutide overview; for cross-compound principles, see how peptides are stored.

The dosage form determines the storage question

Most storage confusion around liraglutide comes from assuming it behaves like a lyophilized research peptide. It does not. Approved liraglutide products are sterile, buffered aqueous solutions in prefilled pens containing a preservative system, so there is no reconstitution step in the approved supply chain. The relevant storage variables are therefore temperature, light exposure, time since first use of a pen, and mechanical handling — not powder hygroscopicity or diluent choice.

Structurally, liraglutide is an acylated analogue of human GLP-1. A structural review of GLP-1 analogues described how modifications to the native peptide backbone and the attachment of fatty-acid chains were used to alter the behaviour of these molecules relative to native GLP-1 (PMID 42727920). In the medicinal-chemistry work that produced semaglutide, researchers reported that acylation strategy and albumin binding were deliberately engineered to improve resistance to enzymatic degradation compared with earlier acylated GLP-1 analogues (PMID 26308095). Those design features govern in vivo stability after administration. They are not a measure of how long a solution survives on a counter, and the literature does not treat the two as interchangeable.

A clinical pharmacology review of liraglutide reported that albumin binding and resistance to dipeptidyl peptidase-4 degradation underpin a pharmacokinetic profile compatible with once-daily administration (PMID 21923591). Broader incretin reviews have described the short circulating life of native GLP-1 and the reason analogues were developed at all (PMID 17098089, PMID 24373234). Again: circulating half-life is a biological parameter, not a shelf-life parameter.

Refrigeration: what approved labeling describes

The following reflects approved product labeling and manufacturer information, not a published trial. Labeling for approved liraglutide pens describes storage of unopened pens in a refrigerator at 2–8 °C (36–46 °F), away from the cooling element, with the pen cap in place to protect the solution from light. Labeling states that liraglutide must not be frozen and that a product that has been frozen is not to be used. After a pen is first used, labeling describes a limited in-use period — commonly stated as 30 days — during which the pen may be kept either refrigerated or at controlled room temperature below 30 °C (86 °F), after which the pen is discarded regardless of remaining volume.

Exact wording varies between the approved liraglutide products, between brand and authorised generic presentations, and between regulatory jurisdictions. The dispensing pharmacy's package insert is the authoritative document for any individual carton, and a prescribing clinician is the appropriate source for any decision about a specific pen.

Lyophilized versus solution formats

Because no approved liraglutide product is a lyophilized powder, there is no manufacturer-stated storage condition for "lyophilized liraglutide" to report. Powdered or compounded liraglutide preparations exist outside the approved supply chain, and their stability depends on the specific formulation, excipients, container closure and manufacturing controls used — none of which are standardised across such products.

The general lyophilized-peptide stability science (not liraglutide-specific, and explicitly flagged as such here) holds that freeze-dried peptides are generally more chemically stable than the same peptide in solution because water participates in hydrolysis, deamidation and other degradation pathways; that residual moisture, oxygen and light accelerate degradation; and that once a lyophilized peptide is dissolved, its chemical and physical stability window shortens substantially. Those principles are widely applied across peptide pharmaceutics, but applying them numerically to a compounded liraglutide powder would require stability data on that exact preparation, which the published literature does not provide.

Compounded and follow-on products: what studies report

Compound-specific evidence does exist on the quality of non-innovator GLP-1 preparations. In a 2024 pharmaceutical sciences study, researchers analysed follow-on and compounded GLP-1 polypeptide drug products and reported differences in properties and quality attributes — including impurity profiles and product characteristics — attributable to the manufacturing and compounding processes used (PMID 39379664). The practical implication drawn in that work is that storage guidance derived from an approved pen cannot be assumed to transfer to a product made by a different process.

Physical stability is the other compound-relevant thread. A 2022 biointerfaces study examined the amyloidogenicity of peptides used to target diabetes and obesity and reported that these sequences can undergo aggregation and fibril formation under defined conditions (PMID 34715595). Aggregation is the physical pathway most often invoked when a peptide solution turns cloudy or develops particulates, and it is temperature-, agitation- and interface-sensitive. The study characterised this behaviour in a laboratory setting; it did not test household storage scenarios for marketed liraglutide pens.

Room temperature and travel

This section again reflects labeling and regulatory practice rather than a published trial. Labeling permits an unopened or in-use pen to sit at controlled room temperature only within the stated in-use period and below the stated upper temperature limit; it does not describe tolerance for heat excursions such as a parked car, a sunlit windowsill or a hold-stowed suitcase. Airline carry-on carriage of injectable medicines with their original labeled carton is a standard accommodation in most jurisdictions, and pharmacists and prescribing clinicians are the appropriate parties to consult about cold-chain arrangements for travel, time-zone changes or extended trips.

No study in the verified literature set measured liraglutide concentration or potency after specific real-world temperature excursions. Claims circulating online about how many hours or days a liraglutide pen "survives" outside a refrigerator are not supported by published excursion data for this product, and are not repeated here.

Freezing

Labeling for approved liraglutide pens prohibits freezing. The mechanistic rationale drawn from general protein and peptide formulation science — again, not liraglutide-specific measurement — is that ice formation concentrates solutes, shifts pH in the freeze-concentrate, and creates new ice–liquid interfaces, all of which can promote aggregation and loss of native structure. The aggregation propensity of this class of peptides under stress conditions was characterised in the 2022 amyloidogenicity study (PMID 34715595). Because a frozen-and-thawed solution can look unchanged while having altered physical quality, labeling treats freezing as disqualifying rather than as something to be judged by appearance.

Signs of degradation described in labeling

Approved labeling describes liraglutide solution as clear and colourless, and directs that product which is cloudy, discoloured, or contains visible particles should not be used. Those are visual acceptance criteria, not analytical ones: chemical degradation products such as deamidated or oxidised species are invisible to the eye and are detected only by chromatographic assay. The 2024 manufacturing and compounding study illustrated the gap, since researchers there used analytical characterisation rather than inspection to identify quality differences between products (PMID 39379664). A pen that looks normal has therefore not been shown to be potent, and no at-home visual check substitutes for storage within labeled conditions.

Handling and Product-Quality Concerns: What Studies Report

The verified literature addresses product quality and clinical outcomes rather than storage-induced harm specifically. The 2024 pharmaceutical research study reported that manufacturing and compounding processes affected the properties and quality of follow-on GLP-1 polypeptide drug products (PMID 39379664). The 2022 study reported that peptides in this therapeutic space can be amyloidogenic under conditions favouring aggregation (PMID 34715595). A review of GLP-1 agonist development described formulation, delivery and tolerability among the ongoing challenges for this drug class (PMID 30372907), and a 2026 endocrine review summarised the current landscape of GLP-1-based medications for type 2 diabetes and obesity (PMID 41054801). In the clinical domain, the FIGHT randomized trial of liraglutide in patients with advanced heart failure and reduced ejection fraction reported that liraglutide did not lead to greater clinical stability after hospitalisation compared with placebo (PMID 27483064). None of these reports quantified the clinical consequences of storing a pen incorrectly; that specific question has not been answered in the cited literature.

What the literature does not establish

• Potency retention of marketed liraglutide after defined heat or freeze excursions — no excursion study appears in the verified set.
• Stability of compounded or powdered liraglutide preparations, which vary by process, as the 2024 study documented for follow-on GLP-1 products (PMID 39379664).
• Whether visual inspection detects chemically degraded but clear solution — it does not, on the analytical logic described above.
• Any storage approach for an individual person, which is a clinical and pharmacy question rather than a literature question.

Work on related molecules — such as the preclinical primate study of the GIPR antagonist AT-7687 combined with a GLP-1 agonist (PMID 39128651) and a review of reward-induced eating and approaches to food cravings (PMID 27718159) — addresses pharmacology rather than handling, and contributes nothing to storage questions.

Summary of the evidence picture

Taken together, the compound-specific literature characterises liraglutide's molecular design and pharmacology (PMID 21923591), the aggregation potential of diabetes- and obesity-targeting peptides (PMID 34715595), and the process-dependence of quality in non-innovator GLP-1 products (PMID 39379664), while the concrete storage parameters — 2–8 °C unopened, a limited in-use period, light protection and no freezing — come from approved product labeling rather than from published trials. This page is for educational purposes only and is not medical advice; consult a licensed physician or pharmacist about any question concerning a prescription medicine, including how a specific product should be stored, transported or discarded.

References

• Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Pharmaceutical Research, 2024)
• Amyloidogenicity of peptides targeting diabetes and obesity (Colloids and Surfaces B: Biointerfaces, 2022)
• Liraglutide: clinical pharmacology and considerations for therapy (Pharmacotherapy, 2011)
• Structural Overview of GLP-1 Analogs (Biomedical Journal, 2026)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Journal of Medicinal Chemistry, 2015)
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (Lancet, 2006)
• Regulation of glucose homeostasis by GLP-1 (Progress in Molecular Biology and Translational Science, 2014)
• Recent updates on GLP-1 agonists: Current advancements & challenges (Biomedicine & Pharmacotherapy, 2018)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (JAMA, 2016)
• AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys (Molecular Metabolism, 2024)
• Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings (Advances in Therapy, 2016)